Pharmaceutical Market Europe • May 2021 • 42-44
APPOINTMENTS
The Institute of Cancer Research
KRISTIAN HELIN
The Institute of Cancer Research, London has appointed Kristian Helin as its chief executive. Helin was founding director of a scientific institute in his native Denmark, and has previously led research centres in Italy and the US, and also founded biotech company EpiTherapeutics. Previously he was director of BRIC, a biotech and innovation institute at the University of Copenhagen. He was also a unit and division director at the European Institute of Oncology in Milan. He will join the ICR in September from Memorial Sloan Kettering Cancer Center in the US, where he currently serves as chair of the cell biology programme and director of the Center for Epigenetics Research. Helin takes over as chief executive from Paul Workman.
Novartis
JAVIER BOIX
Novartis has appointed Javier Boix as global head of communications and engagement. Boix began working at AbbVie prior to the Abbott split, serving as a corporate and internal communications manager. Most recently, he served as head of US communications at AbbVie, after progressing through the organisation. Earlier in his career, Boix worked at Edelman for seven years.
Eli Lilly
DIOGO RAU
Diogo Rau has been appointed as senior vice president and chief information and digital officer at Eli Lilly. Most recently, Rau served as the top executive of information technology for retail and online stores at Apple. Prior to Apple, he was a partner with McKinsey & Company, where he led the North America IT organisation and governance practice.
Bayer
NELSON AMBROGIO
Bayer has promoted Nelson Ambrogio as senior vice president, general manager of oncology. Prior to this, Ambrogio was the senior vice president, general manager of women’s healthcare at Bayer. Before that, he held multiple leadership positions within Bayer worldwide, including general manager of Bayer in Australia and New Zealand. He began his career in sales and marketing at Schering.
GlaxoSmithKline
ANNE BEAL
GlaxoSmithKline (GSK) has appointed Anne Beal to the company’s board as non-executive director. Beal brings extensive healthcare experience to GSK, as a physician and entrepreneur. She is a recognised health policy expert in the development of global and national programmes. Currently, Beal is founder and CEO of AbsoluteJOI Skincare and a member of the board of AcademyHealth.
Bayer
JOHN BERRIOS
Bayer has also announced the promotion of John Berrios to the new role of senior vice president, general manager of women’s healthcare. Berrios has spent five years working at Bayer, most recently as vice president of commercial operations. Prior to joining Bayer, he spent more than 15 years at AstraZeneca across various roles spanning sales, market access and marketing.
Ceylad Oncology
CHARLES MORRIS
Ceylad Oncology has appointed Charles Morris as chief medical officer. Morris has over 20 years of oncology drug development experience. Prior to joining Ceylad, he served as chief medical officer of Radius Health and health leadership positions at PsiOxus Therapeutics, ImmunoGen and Allos Therapeutics. He was also previously vice president of worldwide clinical research at Cephalon and spent time at AstraZeneca.
Montis Biosciences
RENÉ HOET
Montis Biosciences has appointed René Hoet as its chief scientific officer (CSO). Hoet is a molecular immunologist by training, having most recently served as CSO at Imcheck Therapeutics. Prior to this, he was vice president, biologics research at Bayer. Among other prior roles, Hoet also previously led the product-related research, scientific communication and translational research teams at Genmab.
Enthera Pharmaceuticals
CLAUDIA NARDINI
Claudia Nardini has joined Enthera Pharmaceuticals as vice president of research and development. Nardini has 25 years of experience in the biopharmaceutical industry in senior roles across quality control, operations, R&D, regulatory affairs, post-marketing surveillance and marketing. This includes roles at Sartorius Stedim Biotech, Bayer and Kedrion Biopharma across Germany, Italy and the US.
Prothena
HIDEKI GARREN
Hideki Garren has joined Prothena as chief medical officer. Garren joins Prothena from Roche where he was vice president, global head of neuroimmunology, leading Roche’s neuroimmunology franchise team. He has also served as executive director, translational medicine expert in neuroscience at Novartis. Hideki also co-founded Bayhill Therapeutics in 2002 based on a technology platform he co-invented.
Sitryx
IAIN KILTY
Headquartered in Oxford, UK, Sitryx has appointed Iain Kilty as chief scientific officer. Kilty has over 20 years of global biopharmaceutical industry experience. He joins Sitryx from Quench Bio, where he also served as chief scientific officer. Prior to joining Quench, he was vice president preclinical sciences in the inflammation and immunology research unit at Pfizer.
Tubulis
GÜNTER FINGERLE-ROWSON
Tubulis has appointed Günter Fingerle-Rowson as chief medical officer. Fingerle-Rowson has over two decades of academic, biotechnology and pharmaceutical industry experience. Most recently, he worked in global clinical development at MorphoSys and in medical affairs at Johnson & Johnson’s Janssen. He has also held director and leadership roles at Roche.
EXACT THERAPEUTICS
DOMINIC MORELAND
Clinical-stage precision medicine company EXACT THERAPEUTICS has appointed Dominic Moreland as chief financial officer. Moreland has experience in both finance and operations gained from a variety of life sciences companies, including Genzyme, Baxter and Autolus Therapeutics. He is also a chartered accountant and graduate from the London School of Economics, and he began his career at KPMG.
Quercis Pharma
JOHN BOGHOSSIAN
Quercis Pharma has appointed John Boghossian as chief executive officer. Previously, Boghossian led operations and co-led fundraising activities as vice president of operations at COMPASS Pathways, a clinical stage company focused on the development of psilocybin. Prior to this, he was a management consultant in the life sciences practice at the Boston Consulting Group in Europe and the US.
XNK Therapeutics
JOHAN ASCHAN
Johan Aschan has joined XNK Therapeutics as chief medical officer. Aschan joins XNK from Swedish biotech company Oncopeptides, where he was global clinical lead within the company’s clinical development team. He has extensive experience in allogenic stem cell transplantation from the Karolinska University Hospital in Huddinge, Sweden and leadership roles at Janssen.
Atriva Therapeutics
OLAF ALTHAUS
German biopharma company Atriva Therapeutics has appointed Olaf Althaus as chief financial officer. Althaus has a proven track record of over 20 years working in the life sciences industry. Previously, he was co-founder, chief executive officer and chief financial officer of CellMed for 12 years and also served as managing director at AEterna Zentaris.
C4X Discovery
SIMON HARFORD
C4X Discovery has appointed Simon Harford as non-executive director. Harford joins with more than 30 years of significant financial and investor relations expertise in the pharma industry. Currently, he is chief financial officer of Albireo Pharma, and previously held various financial leadership roles at GlaxoSmithKline, including senior vice president of finance, global pharmaceuticals.
Autolus Therapeutics
MARTIN MURPHY
Martin Murphy has joined Autolus Therapeutics as non-executive chairman of the company’s board of directors. Murphy has more than 25 years of experience in the life sciences sector, having joined Autolus’ board as a non-executive director when the company was founded in 2014. He is currently chief executive officer of Syncona Investment Management, a healthcare investment company.
Modra Pharmaceuticals
HEMANSHU SHAH
AND KLAUS SCHOLLMEIER
Modra Pharmaceuticals has appointed Hemanshu Shah and Klaus Schollmeier to its supervisory board. Shah has over 30 years of experience in pharma and biotech companies including Astellas, Bristol Myers Squibb and Johnson & Johnson. Schollmeier previously served as chief executive officer (CEO) of SuppreMol and CEO and chairman of the board of Santhera Pharmaceuticals.
Evonetix
MICHAEL DANIELS
Evonetix has appointed Michael Daniels as head of product management. Daniels brings over 15 years of experience of and expertise in marketing and product management across the biotech sector. His previous roles include director of marketing and product management at Arcis Biotechnology, as well as senior manager of marketing and business development at Cancer Research UK.
DBV Technologies
TIMOTHY MORRIS
French biopharma company DBV Technologies has appointed Timothy Morris to its board of directors. Morris has served as chief operating officer and chief financial officer of Humanigen since August 2020. He has spent more than two decades leading the financial, commercial and manufacturing function at several biopharma companies, including Iovance, AcelRx, VIVUS and Questcor.
McCann Health
SATURNINO IZQUIERDO
Saturnino Izquierdo has been appointed as president, Europe and Latin America (LATAM) at McCann Health. Izquierdo is now set to lead the teams in the network’s four markets across Europe and Latin America. Previously, he served as executive vice president of McCann Health LATAM and EVP, chief of growth global clients at the company.
McCann Health
JONATHAN KUKATHASAN
McCann Health UK has appointed Jonathan Kukathasan as president, after over 15 years spent working at the company. Kukathasan started his career at McCann Health as a production assistant, before progressing to become managing director of McCann Health London in 2018. In his new role, he will lead the strategic direction for all business units within McCann Health UK’s agencies.
Havas Health & You
PAT THISTLETHWAITE
Havas Health & You (HH&Y) has appointed Pat Thistlethwaite as chief experience officer. In addition to taking on this new role, Thistlethwaite will also continue in his role as managing director of Havas Health CX. His prior roles include managing director of data, analytics and activation at Evoke, managing director, North America at Across Health and marketing and commercial roles at Pfizer.
VMLY&Rx
NICHOLE DAVIES
VMLY&Rx has announced the appointment of Nichole Davies as global chief strategy officer. Davies will head up a new global strategic practice at VMLY&Rx, aiming to deliver and enable connected health strategies for clients. Prior to joining VMLY&Rx, Davies worked as global chief strategy officer at WPP Health Practice, and previously served as chief strategy officer for Wunderman Thompson Health.
Lucid Group
CLARE REYNOLDS
Lucid Group has promoted Clare Reynolds to director of business development and commercial integration. Reynolds initially joined Lucid in 2009 as business unit director and since then, she has progressed through the ranks at the medcomms company, most recently working as senior managing partner. Prior to Lucid, she served as marketing director, HIV International for Gilead Sciences.
Havas NOW
ROBERT WAINWRIGHT
AND BAM ZAHRAIE
Robert Wainwright and Bam Zahraie have been promoted to associate managing directors of Havas NOW – the innovation hub of Havas Health & You (HH&Y). Wainwright has played a key role in developing innovation at HH&Y since joining the company over ten years ago. Zahraie brings extensive experience in digital and technology businesses to his role at HH&Y.
Hanover Health
DONNA CURRAN
Donna Curran has been appointed as associate director at Hanover Health. Curran most recently worked for Ruder Finn as associate director for over seven years. She has also previously held roles at a number of agencies including Packer Forbes Communications, where she served as account director, as well as Racepoint Group and Euro RSCG.
Hanover Health
MARK MACDONALD
Mark MacDonald has also been appointed as associate director at Hanover Health. MacDonald joins from the Stroke Association, where he worked for just over five years. Most recently, he worked as systems leadership development lead at the UK-based charity. Prior to this, he served in a number of roles for the Liberal Democrats over a period of almost two years.
Healthware Group
YANNICK VALENTI
Healthware Group has appointed Yannick Valenti as digital strategy and customer engagement director in the UK. Valenti joins Healthware from Ogilvy Health, where he spent three years working as digital strategy director. Prior to that, he was European general manager for SRAX and also previously served as head of digital strategies at Sudler International.
Weber Shandwick
JOHN-KENNETH BILLINGSLEY
Weber Shandwick has appointed John-Kenneth Billingsley as executive vice president, health policy and advocacy. Prior to joining Weber Shandwick, Billingsley served as vice president and global head of external engagement for UCB. He has also worked in external affairs leadership roles at Novartis and GlaxoSmithKline (GSK), and has served on the boards of several international industry organisations.
Havas Just::
CORIN BAIRD
Havas Just:: has appointed Corin Baird as head of digital to underpin its medcomms and PR divisions. Baird joins the team with a varied background in digital marketing, including head of creative solutions at Buzzfeed, Huffington Post and The Guardian. He has also served in a number of leadership roles at agencies Nitro and Sudler.
Lexington Health
ED MCRANDAL
AND WILL CULLIFORD
Lexington Health has appointed Ed McRandal to head of health and Will Culliford as director. McRandal joined Lexington three years ago, serving as deputy head of the health team. Culliford also joined the agency three years ago, having previously worked as policy and public affairs manager at the Royal College of Surgeons of England.